1 ANNEX, Regulation (EU) 2015/1221

In forcesince 24 Jul 2015

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1)

Table 3.1 is amended as follows:

(a)

the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 |

Ox. Liq. 2

Skin Corr. 1A

H272

H314

GHS03

GHS05

Dgr

H272

H314

EUH071 |

Skin Corr. 1A; H314: C ≥ 20 %

Skin Corr. 1B; H314: 5 % ≤ C < 20 %

Ox. Liq. 2; H272: C ≥ 99 %

Ox. Liq. 3; H272: 99 % > C ≥ 65 %

B

015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 |

Water-react. 1

Acute Tox. 2

Acute Tox. 3

Acute Tox. 1

Eye Dam. 1

Aquatic Acute 1

H260

H300

H311

H330

H318

H400

GHS02

GHS06

GHS05

GHS09

Dgr

H260

H300

H311

H330

H318

H400

EUH029

EUH032

M = 100 |

031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 |

Repr. 1B

Carc. 1B

STOT RE 1

H360F

H350

H372 (respiratory and haematopoietic systems)

GHS08

Dgr

H360F

H350

H372 (respiratory and haematopoietic systems)

050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — |

Repr. 1B

Acute Tox. 3

Acute Tox. 4*

STOT RE 1

Skin Irrit. 2

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H360FD

H301

H312

H372**

H315

H319

H400

H410

GHS08

GHS06

GHS09

Dgr

H360FD

H301

H312

H372**

H315

H319

H410

*

STOT RE 1; H372: C ≥ 1 %

STOT RE 2; H373: 0,25 % ≤ C < 1 %

Skin Irrit. 2; H315:C ≥ 1 %

Eye Irrit. 2; H319:C ≥ 1 %

M = 10

A

1

603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 |

Flam. Liq. 2

Carc. 2

Acute Tox. 4*

Acute Tox. 4*

Acute Tox. 4*

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

H225

H351

H302

H312

H332

H335

H315

H319

GHS02

GHS08

GHS07

Dgr

H225

H351

H302

H312

H332

H335

H315

H319

603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 |

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H361d***

H302

H400

H410

GHS08

GHS07

GHS09

Wng

H361d***

H302

H410

M = 1

M = 10

606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 |

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d***

H400

H410

GHS08

GHS09

Wng

H361d***

H410

M = 10

M = 100

607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 |

Skin Irrit. 2

Eye Irrit. 2

Aquatic Chronic 3

H315

H319

H412

GHS07

Wng

H315

H319

H412

613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 |

Carc. 2

Acute Tox. 3

Acute Tox. 4

Eye Dam. 1

Aquatic Chronic 1

H351

H301

H332

H318

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H351

H301

H332

H318

H410

M = 10 |

613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 |

Repr. 2

STOT RE 2

Skin Corr. 1C

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H361d

H373 (liver)

H314

H317

H400

H410

GHS08

GHS05

GHS07

GHS09

Dgr

H361d

H373 (liver)

H314

H317

H410

EUH071 |

M = 1

M = 1

613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 |

Carc. 2

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H317

H410

M = 1

M = 1

613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 |

Acute Tox. 3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H400

H410

GHS06

GHS09

Dgr

H331

H301

H410

M = 1000

M = 1000

(b)

the following entries are inserted in accordance with the order of the entries set out in Table 3.1:

Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 |

GSH07

Wng

H319 | | |

604-092-00-9 |

phenol, dodecyl-, branched [1];

phenol, 2-dodecyl-, branched;

phenol, 3-dodecyl-, branched;

phenol, 4-dodecyl-, branched;

phenol, (tetrapropenyl) derivatives [2]

310-154-3 [1] |

121158-58-5 [1]

74499-35-7 [2]

Skin Corr. 1C

Aquatic Acute 1

Aquatic Chronic 1

H314

H400

H410

GHS05

GHS09

Dgr

H314

H410

M = 10

M = 10

606-148-00-8 |

carvone (ISO);

2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]

d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]

l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]

202-759-5 [1]

218-827-2 [2]

229-352-5 [3]

99-49-0 [1]

2244-16-8 [2]

6485-40-1 [3]

Skin Sens. 1 | H317 |

GHS07

Wng

H317 | | |

606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | — | 335104-84-2 |

Repr. 2

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H361d

H373 (eyes, kidneys, liver)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361d

H373 (eyes, kidneys, liver)

H317

H410

M = 100

M = 10

607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 |

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373 (kidneys)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373 (kidneys)

H317

H410

M = 1

M = 1

607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 |

Skin Corr. 1C

Aquatic Chronic 3

H314

H412

GHS05

Dgr

H314

H412

607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 |

Skin Irrit. 2

Eye Irrit. 2

Aquatic Chronic 3

H315

H319

H412

GHS07

Wng

H315

H319

H412

607-710-00-5 | 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD |

GHS08

Dgr

H360FD | | |

607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 |

Repr. 2

STOT SE 3

Eye Irrit. 2

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H335

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361fd

H335

H319

H317

H410

M = 1

M = 1

607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 |

Repr. 2

STOT RE 2

Skin Corr. 1C

Skin Sens. 1A

Aquatic Chronic 1

H361d

H373 (liver)

H314

H317

H410

GHS08

GHS05

GHS07

GHS09

Dgr

H361d

H373 (liver)

H314

H317

H410

EUH071 | M = 1 |

607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 |

Acute Tox. 3

Acute Tox. 2

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H301

H330

H317

H400

H410

GHS06 GHS09

Dgr

H301

H330

H317

H410

M = 100

M = 1000

607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 |

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 100

M = 10

607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 |

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373

H317

H410

M = 1

M = 1

613-319-00-0 | imidazole | 206-019-2 | 288-32-4 |

Repr. 1B

Acute Tox. 4

Skin Corr. 1C

H360D

H302

H314

GHS08

GHS07

GHS05

Dgr

H360D

H302

H314

613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 |

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 10

M = 10

616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 1

616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 |

Carc. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H373 (eyes, kidneys)

H400

H410

GHS08

GHS09

Wng

H351

H373 (eyes, kidneys)

H410

M = 1000

M = 100

616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 |

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H317

H400

H410

GHS07

GHS09

Wng

H302

H317

H410

M = 10

M = 10

616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Acute Tox. 4 | H302 |

GHS07

Wng

H302 | | |

616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 |

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

M = 1

M = 1

(2)

Table 3.2 is amended as follows:

(a)

the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes

007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 |

O; R8

C; R35

O; C

R: 8-35

S: (1/2-)26-28- 36/37/39-45-63

O; R8: C ≥ 65 %

C; R35: C ≥ 20 %

C; R34: 5 % ≤ C < 20 %

B

015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 |

F; R15/29

T+; R26/28

Xn; R21

R32

Xi; R38-41

N; R50

F; T+; N

R: 15/29-21-26/28-32-38-41-50

S:(1/2-)26-28-30-36/37/39-43-45-60-61

N; R50: C ≥ 0,25 % |

031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 |

Repr. Cat. 2; R60

Carc. Cat. 2; R45

T; R48/23

T

R: 45-48/23-60

S: 45-53

E

050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — |

Repr. Cat. 2; R60-61

T; R25-48/23/25

Xn; R21

Xi; R36/38

N; R50-53

T; N

R: 21-25-36/38-48/23/25-50/53-60-61

S: 45-53-60-61

T; R25: C ≥ 2,5 %

Xn; R22: 0,25 % ≤ C < 2,5 %

Xn: R21: C ≥ 1 %

T; R48/23/25: C ≥ 1 %

Xn; R48/20/22: 0,25 % ≤ C < 1 %

Xi; R36/38: C ≥ 1 %

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

A

1

603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 |

F; R11

Carc. Cat. 3; R40

Xn; R20/21/22

Xi; R36/37/38

F; Xn

R: 11-20/21/22-36/37/38-40-

S: (2-)9-16-29-36/37-46

603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 |

Repr. Cat. 3; R63

Xn; R22

N; R50-53

Xn; N

R: 22-50/53-63

S: (2-)22-36/37-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C <25 %

R52-53: 0,25 % ≤ C < 2,5 %

606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 |

Repr. Cat. 3; R63

N; R50-53

Xn; N

R: 50/53-63

S: (2-)36/37-60-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 |

Xi; R36/38

N; R51-53

Xi; N

R: 36/38-51/53

S: (2-)46-61

613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 |

Carc. Cat. 3; R40

Xn; R20/22

Xi; R41

N; R51-53

Xn; N

R: 20/22-40-41-51/53

S: (2-)26-36/37/39-46-61

613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 |

Repr. Cat. 3; R63

C; R34

R43

N; R50-53

C; N

R: 34-43-50/53-63

S: (1/2-)26-28-36/37/39-45-60-61

C; R34: C ≥ 10 %

Xi; R36/37/38: 5 % ≤ C < 10 %

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 |

Carc. Cat. 3; R40

Xn; R22

R43

N; R50-53

Xn; N

R: 22-40-43-50/53

S: (2-)36/37-46-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 |

T; R23/25

N; R50-53

T; N

R: 23/25-50/53

S: (1/2-)36/37-45-60-61

N; R50-53: C ≥ 0,025 %

N; R51-53: 0,0025 % ≤ C < 0,025 %

R52-53: 0,00025 % ≤ C < 0,0025 %

(b)

the following entries are inserted in accordance with the order of the entries set out in Table 3.2:

Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes

019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Xi; R36 |

Xi

R: 36

S: (2-)25-46

604-092-00-9 |

phenol, dodecyl-, branched [1];

phenol, 2-dodecyl-, branched;

phenol, 3-dodecyl-, branched;

phenol, 4-dodecyl-, branched;

phenol, (tetrapropenyl) derivatives [2]

310-154-3 [1]-[2] |

121158-58-5 [1]

74499-35-7 [2]

C; R34

N; R50-53

C; N

R: 34-50/53

S: (1/2-)26-36/37/39-45-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

606-148-00-8 |

carvone (ISO);

2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]

d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]

l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]

202-759-5 [1]

218-827-2 [2]

229-352-5 [3]

99-49-0 [1]

2244-16-8 [2]

6485-40-1 [3]

R43 |

Xi

R: 43

S: (2-)24-37

606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | | 335104-84-2 |

Repr. Cat. 3; R63

Xn; R48/22

R43

N; R50-53

Xn; N

R: 43-48/22-50/53-63

S: (2-)36/37-46-60-61

N; R50-53: C ≥ 0,25 %

N; R51-53: 0,025 % ≤ C < 0,25 %

R52-53: 0,0025 % ≤ C < 0,025 %

607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 |

Xn; R48/22

R43

N; R50-53

Xn; N

R: 43-48/22-50/53

S: (2-)24-37-46-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 |

C; R34

N; R51-53

C; N

R: 34-51/53

S: (1/2-)26-36/37/39-45-61

607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 |

Xi; R36/38

N; R51-53

Xi; N

R: 36/38-51/53

S: (2-)25-46-61

607-710-00-5 | 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. Cat. 2; R60-61 |

T

R: 60-61

S: 53-45

607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 |

Repr. Cat. 3; R62-63

Xi; R36/37

R43

N; R50-53

Xn; N

R: 36/37-43-50/53-62-63

S: (2-)36/37-60-61

Xi; R43: C ≥ 0,1 %

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 |

Repr. Cat. 3; R63

C; R34

R43

N; R51-53

C; N

R: 34-43-51/53-63

S: (1/2-)26-28-36/37/39-45-61

C; R34: C ≥ 10 %

Xi: R36/37/38: 5 % ≤ C < 10 %

607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 |

T+; R26

Xn; R22

R43

N; R50-53

T+; N

R: 22-26-43-50/53

S: (1/2-)28-36/37-45-60-61-63

N; R50-53: C ≥ 0,25 %

N; R51-53: 0,025 % ≤ C < 0,25 %

R52-53: 0,0025 % ≤ C < 0,025 %

607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 |

Carc. Cat. 3; R40

N; R50-53

Xn; N

R: 40-50/53

S: (2-)36/37-60-61

N; R50-53: C ≥ 0,25 %

N; R51-53: 0,025 % ≤ C < 0,25 %

R52-53: 0,0025 % ≤ C < 0,025 %

607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 |

R43

N; R50-53

Xi; N

R: 43-50/53

S: (2-)24-37-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

613-319-00-0 | imidazole | 206-019-2 | 288-32-4 |

Repr. Cat 2; R61

Xn; R22

C; R34

T; C

R: 22-34-61

S: 53-45

613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 |

Carc. Cat. 3; R40

N; R50-53

Xn; N

R: 40-50/53

S: (2-)36/37-60-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | N; R50-53 |

N

R: 50/53

S: 60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C <25 %

R52-53: 0,25 % ≤ C < 2,5 %

616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 |

Carc. Cat. 3; R40

Xn; R48/22

N; R50-53

Xn; N

R: 40-48/22-50/53

S: (2-)36/37-46-60-61

N; R50-53: C ≥ 0,025 %

N; R51-53: 0,0025 % ≤ C < 0,025 %

R52/53: 0,00025 % ≤ C < 0,0025 %

616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 |

Xn; R22

R43

N; R50-53

Xn; N

R: 22-43-50/53

S: (2-)24-37-60-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Xn; R22 |

Xn

R: 22

S: (2-)46

616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 |

Xn; R22

N; R50-53

Xn; N

R: 22-50/53

S: (2-)60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %